MedOptions

Belkins
MedOptions is growing. The nation’s leading provider of behavioral health services to skilled nursing and assisted living facilities continues to expand and has local opportunities for nurse practitioners to join our team of 800 clinicians and support staff. MedOptions partners with skilled nursing and assisted living facilities across the nation to provide expert behavioral health services, improving the overall mental health in elderly patients through the use of memory care evaluations, medication management, and behavioral interventions. Our multidisciplinary team consists of psychiatrists, nurse practitioners, clinical psychologists and clinical social workers. They are experienced in dementia care and Alzheimer’s care, long term behavioral health care in elderly populations, and memory care services.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

INDUSTRIAL IMPACT

SUTRO BIOPHARMA AND TASLY BIOPHARMACEUTICALS ENTER INTO EXCLUSIVE LICENSE AGREEMENT FOR STRO-002 IN GREATER CHINA

Sutro Biopharma | December 28, 2021

news image

Sutro Biopharma, Inc. a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics, announced an exclusive license agreement with Tasly Biopharmaceuticals Co., Ltd. a holding subsidiary of Tasly Pharmaceutical Group Co., Ltd. for the development and commercialization of STRO-002 in Greater China, consisting of mainland China, Hong Kong, Macau and Ta...

Read More

COLLAPSE OF £550M DEAL TO SELL WOODFORD'S BIOTECHS SPARKS FIRE SALE FEARS

FierceBiotech | February 10, 2020

news image

A £550 million ($711 million) deal to find new homes for Neil Woodford’s biotech holdings has collapsed, raising the prospect that stakes in companies including Immunocore will be auctioned off for knock-down prices. Woodford became a go-to source of money for private British biotechs in the years after he left Invesco to set up his own fund. However, the illiquid nature of Woodford’s holdings in such companies became a problem as more and more investors began taking money out ...

Read More

RESEARCH

ALIVAMAB DISCOVERY SERVICES IS EXPANDING THE DRUG DISCOVERY PLATFORM WITH THE INTRODUCTION OF NEW ANTIBODY ENGINEERING DEPARTMENT

AlivaMab | May 13, 2021

news image

AlivaMab Discovery Services, LLC ("ADS"), a pioneer in the discovery of superior antibody therapeutics, announced today the formation of its new Antibody Engineering Department, headed by Jonah Rainey, Ph.D. Jonah joins ADS as Vice President of Antibody Engineering, bringing 15 years of experience from Macrogenics Inc. in antibody engineering, discovery, and development, MedImmune, LLC/AstraZeneca PLC, Gritstone Bio, Inc., and, most recently, Immetas Therapeutics, Inc. Jonah's expe...

Read More

BOOST BIOMES ANNOUNCES CLOSE OF SERIES A AND CO-DEVELOPMENT AGREEMENT WITH LEAD INVESTOR, YARA INTERNATIONAL, FOR BIOSTIMULANTS PRODUCTS

Boost Biomes | June 25, 2020

news image

US-based food and agriculture biotech startup Boost Biomes and global crop nutrition company, Yara International ASA, announced today the close of Boost's USD 5 million series A equity round as well as a joint development agreement between the two companies. Yara's investment amounts to USD 3 million. Existing investors, including Viking Global Investors and Y Combinator, participated in the close.With this partnership in place, Boost and Yara will expand current efforts to co-deve...

Read More
news image

INDUSTRIAL IMPACT

SUTRO BIOPHARMA AND TASLY BIOPHARMACEUTICALS ENTER INTO EXCLUSIVE LICENSE AGREEMENT FOR STRO-002 IN GREATER CHINA

Sutro Biopharma | December 28, 2021

Sutro Biopharma, Inc. a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics, announced an exclusive license agreement with Tasly Biopharmaceuticals Co., Ltd. a holding subsidiary of Tasly Pharmaceutical Group Co., Ltd. for the development and commercialization of STRO-002 in Greater China, consisting of mainland China, Hong Kong, Macau and Ta...

Read More
news image

COLLAPSE OF £550M DEAL TO SELL WOODFORD'S BIOTECHS SPARKS FIRE SALE FEARS

FierceBiotech | February 10, 2020

A £550 million ($711 million) deal to find new homes for Neil Woodford’s biotech holdings has collapsed, raising the prospect that stakes in companies including Immunocore will be auctioned off for knock-down prices. Woodford became a go-to source of money for private British biotechs in the years after he left Invesco to set up his own fund. However, the illiquid nature of Woodford’s holdings in such companies became a problem as more and more investors began taking money out ...

Read More
news image

RESEARCH

ALIVAMAB DISCOVERY SERVICES IS EXPANDING THE DRUG DISCOVERY PLATFORM WITH THE INTRODUCTION OF NEW ANTIBODY ENGINEERING DEPARTMENT

AlivaMab | May 13, 2021

AlivaMab Discovery Services, LLC ("ADS"), a pioneer in the discovery of superior antibody therapeutics, announced today the formation of its new Antibody Engineering Department, headed by Jonah Rainey, Ph.D. Jonah joins ADS as Vice President of Antibody Engineering, bringing 15 years of experience from Macrogenics Inc. in antibody engineering, discovery, and development, MedImmune, LLC/AstraZeneca PLC, Gritstone Bio, Inc., and, most recently, Immetas Therapeutics, Inc. Jonah's expe...

Read More
news image

BOOST BIOMES ANNOUNCES CLOSE OF SERIES A AND CO-DEVELOPMENT AGREEMENT WITH LEAD INVESTOR, YARA INTERNATIONAL, FOR BIOSTIMULANTS PRODUCTS

Boost Biomes | June 25, 2020

US-based food and agriculture biotech startup Boost Biomes and global crop nutrition company, Yara International ASA, announced today the close of Boost's USD 5 million series A equity round as well as a joint development agreement between the two companies. Yara's investment amounts to USD 3 million. Existing investors, including Viking Global Investors and Y Combinator, participated in the close.With this partnership in place, Boost and Yara will expand current efforts to co-deve...

Read More